{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:47:31Z","timestamp":1791946051596,"version":"4.3.4"},"reference-count":121,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.10229","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T12:07:22Z","timestamp":1621944442000},"source":"Crossref","is-referenced-by-count":72,"title":["Updates and new medical treatments for vitiligo (Review)"],"prefix":"10.3892","volume":"22","author":[{"given":"David","family":"Kubelis\u2011L\u00f3pez","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital \u2018Dr.\u00a0Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Nuevo Le\u00f3n 64460, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Zapata\u2011Salazar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital \u2018Dr.\u00a0Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Nuevo Le\u00f3n 64460, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Said\u2011Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, Faculty of Medicine and University Hospital \u2018Dr.\u00a0Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Nuevo Le\u00f3n 64460, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"S\u00e1nchez\u2011Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, Faculty of Medicine and University Hospital \u2018Dr.\u00a0Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Nuevo Le\u00f3n 64460, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Salinas\u2011Santander","sequence":"additional","affiliation":[{"name":"Department of Research, Faculty of Medicine Saltillo Unit, Universidad Aut\u00f3noma de Coahuila, Saltillo 25000, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herminia","family":"Mart\u00ednez\u2011Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, Faculty of Medicine and University Hospital \u2018Dr.\u00a0Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Nuevo Le\u00f3n 64460, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo","family":"V\u00e1zquez\u2011Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital \u2018Dr.\u00a0Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Nuevo Le\u00f3n 64460, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Wollina","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology and Skin Cancer Center, St\u00e4dtisches Klinikum Dresden, D\u201101067 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torello","family":"Lotti","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University of Rome G. Marconi, I\u201100193 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ocampo\u2011candiani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital \u2018Dr.\u00a0Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Nuevo Le\u00f3n 64460, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"key20210729111942_b1-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"key20210729111942_b2-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kr\u00fcger","year":"2012","journal-title":"Int J Dermatol"},{"key":"key20210729111942_b3-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1034\/j.1600-0749.2003.00070.x","article-title":"A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?","volume":"16","author":"Gauthier","year":"2003","journal-title":"Pigment Cell Res"},{"issue":"1144","key":"key20210729111942_b4-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071144","article-title":"Signaling pathways in melanogenesis","volume":"17","author":"D'Mello","year":"2016","journal-title":"Int J Mol Sci"},{"key":"key20210729111942_b5-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1590\/s0365-05962013000100009","article-title":"Mechanisms regulating melanogenesis","volume":"88","author":"Videira","year":"2013","journal-title":"An Bras Dermatol"},{"key":"key20210729111942_b6-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1096\/fj.06-6649rev","article-title":"Human skin pigmentation: Melanocytes modulate skin color in response to stress","volume":"21","author":"Costin","year":"2007","journal-title":"FASEB J"},{"key":"key20210729111942_b7-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1084\/jem.184.4.1385","article-title":"Innervation of melanocytes in human skin","volume":"184","author":"Hara","year":"1996","journal-title":"J Exp Med"},{"key":"key20210729111942_b8-ETM-0-0-10229","author":"Ohbayashi"},{"key":"key20210729111942_b9-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1152\/physrev.00044.2003","article-title":"Melanin pigmentation in mammalian skin and its hormonal regulation","volume":"84","author":"Slominski","year":"2004","journal-title":"Physiol Rev"},{"key":"key20210729111942_b10-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1755-148X.2011.00898.x","article-title":"L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions","volume":"25","author":"Slominski","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"key20210729111942_b11-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","article-title":"Vitiligo: Pathogenesis, clinical variants and treatment approaches","volume":"15","author":"Iannella","year":"2016","journal-title":"Autoimmun Rev"},{"key":"key20210729111942_b12-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: Focus on clinical aspects, immunopathogenesis, and therapy","volume":"54","author":"Boniface","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"key20210729111942_b13-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/exd.13677","article-title":"The convergence theory for vitiligo: A reappraisal","volume":"28","author":"Kundu","year":"2019","journal-title":"Exp Dermatol"},{"key":"key20210729111942_b14-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1001\/archderm.138.2.273","article-title":"Vitiligo and epidermal microenvironment: Possible involvement of keratinocyte-derived cytokines","volume":"138","author":"Moretti","year":"2002","journal-title":"Arch Dermatol"},{"key":"key20210729111942_b15-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b16-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.det.2016.11.007","article-title":"Medical and maintenance treatments for vitiligo","volume":"35","author":"Passeron","year":"2017","journal-title":"Dermatol Clin"},{"issue":"CD003263","key":"key20210729111942_b17-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003263.pub5","article-title":"Interventions for vitiligo","author":"Whitton","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key20210729111942_b18-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: The European dermatology forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"key":"key20210729111942_b19-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1365-2133.2008.08881.x","article-title":"Guideline for the diagnosis and management of vitiligo","volume":"159","author":"Gawkrodger","year":"2008","journal-title":"Br J Dermatol"},{"key":"key20210729111942_b20-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/archderm.134.12.1532","article-title":"Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature","volume":"134","author":"Njoo","year":"1998","journal-title":"Arch Dermatol"},{"key":"key20210729111942_b21-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1590\/abd1806-4841.20142717","article-title":"Vitiligo-Part 2-classification, histopathology and treatment","volume":"89","author":"Faria","year":"2014","journal-title":"An Bras Dermatol"},{"key":"key20210729111942_b22-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Current and emerging treatments for vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b23-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/ddg.13680","article-title":"Therapeutic management of vitiligo","volume":"16","author":"Bleuel","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"key20210729111942_b24-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/14740338.2020.1729737","article-title":"Safety of the current drug treatments for vitiligo","volume":"19","author":"Lotti","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"key20210729111942_b25-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jaad.2006.08.017","article-title":"High-potency steroid use in children with vitiligo: A retrospective study","volume":"56","author":"Kwinter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b26-ETM-0-0-10229","first-page":"150","article-title":"\u2018Soft steroids\u2019 o corticoides suaves en Dermatolog\u00eda Pedi\u00e1trica","volume":"3","author":"Ballona","year":"2005","journal-title":"Dermatol Pediatr Lat"},{"key":"key20210729111942_b27-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jaad.2010.10.043","article-title":"Vitiligo: A comprehensive overview Part II: Treatment options and approach to treatment","volume":"65","author":"Felsten","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b28-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: A systematic review and Meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"key20210729111942_b29-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2019.07.108","article-title":"The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: A systematic review and meta-analysis","volume":"82","author":"Chang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b30-ETM-0-0-10229","author":"Ebrahim"},{"key":"key20210729111942_b31-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/jocd.13193","article-title":"Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo","volume":"19","author":"Abd-Elazim","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"key20210729111942_b32-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41574-019-0312-5","article-title":"New aspects of vitamin D metabolism and action-addressing the skin as source and target","volume":"16","author":"Bikle","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"key20210729111942_b33-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"key20210729111942_b34-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jsbmb.2016.09.024","article-title":"Endogenously produced nonclassical vitamin D hydroxy-metabolites act as \u2018biased\u2019 agonists on VDR and inverse agonists on ROR\u03b1 and ROR\u03b3","volume":"173","author":"Slominski","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20210729111942_b35-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12013-020-00913-6","article-title":"Photoprotective properties of Vitamin D and lumisterol hydroxyderivatives","volume":"78","author":"Slominski","year":"2020","journal-title":"Cell Biochem Biophys"},{"key":"key20210729111942_b36-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1096\/fj.13-242040","article-title":"ROR\u03b1 and ROR\u03b3 are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D","volume":"28","author":"Slominski","year":"2014","journal-title":"FASEB J"},{"key":"key20210729111942_b37-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41435-020-0096-6","article-title":"Extra-adrenal glucocorticoid biosynthesis: Implications for autoimmune and inflammatory disorders","volume":"21","author":"Slominski","year":"2020","journal-title":"Genes Immun"},{"key":"key20210729111942_b38-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2310\/JIM.0b013e31821b8755","article-title":"Vitamin D and the immune system","volume":"59","author":"Aranow","year":"2011","journal-title":"J Investig Med"},{"key":"key20210729111942_b39-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-3083.2002.00407.x","article-title":"Treatment of vitiligo by topical calcipotriol","volume":"16","author":"Chiav\u00e9rini","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20210729111942_b40-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2133.2008.08906.x","article-title":"Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo","volume":"160","author":"Rodr\u00edguez-Mart\u00edn","year":"2009","journal-title":"Br J Dermatol"},{"key":"key20210729111942_b41-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1468-3083.2006.01420.x","article-title":"Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo","volume":"20","author":"Kumaran","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20210729111942_b42-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/jocd.12704","article-title":"Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo","volume":"18","author":"Ibrahim","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"key20210729111942_b43-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4103\/2279-042X.108375","article-title":"The effect of pseudocatalase\/superoxide dismutase in the treatment of vitiligo: A pilot study","volume":"1","author":"Naini","year":"2012","journal-title":"J Res Pharm Pract"},{"key":"key20210729111942_b44-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-4632.2008.03660.x","article-title":"From basic research to the bedside: Efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo","volume":"47","author":"Schallreuter","year":"2008","journal-title":"Int J Dermatol"},{"key":"key20210729111942_b45-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1365-2133.2009.09252.x","article-title":"A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo","volume":"161","author":"Bakis-Petsoglou","year":"2009","journal-title":"Br J Dermatol"},{"key":"key20210729111942_b46-ETM-0-0-10229","author":"Alshiyab"},{"issue":"e13215","key":"key20210729111942_b47-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13215","article-title":"Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature","volume":"33","author":"Agarwal","year":"2020","journal-title":"Dermatol Ther"},{"key":"key20210729111942_b48-ETM-0-0-10229","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archderm.1983.01650330014006","article-title":"Topically administered fluorouracil in vitiligo","volume":"119","author":"Tsuji","year":"1983","journal-title":"Arch Dermatol"},{"key":"key20210729111942_b49-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/CCID.S225881","article-title":"Effect of Topical 5-fluorouracil alone versus its combination with erbium:YAG (2940 nm) laser in treatment of vitiligo","volume":"13","author":"Abdelwahab","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"key20210729111942_b50-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/j.1365-4632.2007.03226.x","article-title":"Comparative evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical placentrex gel in localized stable vitiligo","volume":"46","author":"Sethi","year":"2007","journal-title":"Int J Dermatol"},{"key":"key20210729111942_b51-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1473-2165.2006.00240.x","article-title":"Treatment of periungual vitiligo with erbium-YAG-laser plus 5-flurouracil: A left to right comparative study","volume":"5","author":"Anbar","year":"2006","journal-title":"J Cosmet Dermatol"},{"key":"key20210729111942_b52-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/14764172.2014.1003241","article-title":"Carbon dioxide laser plus topical 5-fluorouracil: A new combination therapeutic modality for acral vitiligo","volume":"17","author":"Mohamed","year":"2015","journal-title":"J Cosmet Laser Ther"},{"key":"key20210729111942_b53-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/jocd.12440","article-title":"Comparison between the efficacy of microneedling combined with 5-fluorouracil vs. microneedling with tacrolimus in the treatment of vitiligo","volume":"17","author":"Mina","year":"2018","journal-title":"J Cosmet Dermatol"},{"issue":"e13013","key":"key20210729111942_b54-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13013","article-title":"Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature","volume":"32","author":"Abdelmaksoud","year":"2019","journal-title":"Dermatol Ther"},{"key":"key20210729111942_b55-ETM-0-0-10229","author":"Eldelee"},{"key":"key20210729111942_b56-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/jocd.12443","article-title":"Bimatoprost ophthalmic solution in facial vitiligo","volume":"17","author":"Jha","year":"2018","journal-title":"J Cosmet Dermatol"},{"key":"key20210729111942_b57-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/jocd.13648","article-title":"Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study","volume":"20","author":"Kanokrungsee","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"e13175","key":"key20210729111942_b58-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13175","article-title":"Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double-blind clinical trial study","volume":"33","author":"Nowroozpoor Dailami","year":"2020","journal-title":"Dermatol Ther"},{"key":"key20210729111942_b59-ETM-0-0-10229","first-page":"41","article-title":"Comparative study of efficacy and safety of topical active fragment of basic fibroblast growth factor (B FGF) 0.1% solution V\/S betamethasone valerate 0.1% ointment in the treatment of vitiligo patients","volume":"14","author":"Kamala Subhashini","year":"2015","journal-title":"IOSR J Dental Med Sci"},{"issue":"e13109","key":"key20210729111942_b60-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13109","article-title":"Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus Tacrolimus 0.1% ointment versus Tacrolimus 0.1% ointment in the treatment of stable vitiligo","volume":"32","author":"Shah","year":"2019","journal-title":"Dermatol Ther"},{"key":"key20210729111942_b61-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b62-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","article-title":"Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: The Vitiligo Area Scoring Index","volume":"140","author":"Hamzavi","year":"2004","journal-title":"Arch Dermatol"},{"key":"key20210729111942_b63-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b64-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"key20210729111942_b65-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"key":"key20210729111942_b66-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1046\/j.1365-4362.1999.00623.x","article-title":"The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients","volume":"38","author":"Kim","year":"1999","journal-title":"Int J Dermatol"},{"key":"key20210729111942_b67-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1046\/j.1365-4362.2000.00006.x","article-title":"Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo","volume":"39","author":"Seiter","year":"2000","journal-title":"Int J Dermatol"},{"key":"key20210729111942_b68-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000251114","article-title":"Treatment of vitiligo with oral corticosteroids","volume":"153","author":"Imamura","year":"1976","journal-title":"Dermatology"},{"key":"key20210729111942_b69-ETM-0-0-10229","first-page":"135","article-title":"The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patient","volume":"69","author":"Banerjee","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"key20210729111942_b70-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-4362.1993.tb02754.x","article-title":"Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease","volume":"32","author":"Pasricha","year":"1993","journal-title":"Int J Dermatol"},{"key":"key20210729111942_b71-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2310\/7750.2013.12053","article-title":"Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo","volume":"17","author":"Kanwar","year":"2013","journal-title":"J Cutan Med Surg"},{"key":"key20210729111942_b72-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1067\/mjd.2001.113475","article-title":"Oral dexamethasone pulse treatment for vitiligo","volume":"44","author":"Radakovic-Fijan","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"e12923","key":"key20210729111942_b73-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12923","article-title":"Apremilast is effective in controlling the progression of adult vitiligo: A case series","volume":"32","author":"Majid","year":"2019","journal-title":"Dermatol Ther"},{"issue":"2386234","key":"key20210729111942_b74-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2386234","article-title":"Repigmentation of tenacious vitiligo on apremilast","volume":"2017","author":"Huff","year":"2017","journal-title":"Case Rep Dermatol Med"},{"key":"key20210729111942_b75-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"key20210729111942_b76-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.abd.2019.08.032","article-title":"Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation","volume":"95","author":"Komnitski","year":"2020","journal-title":"An Bras Dermatol"},{"key":"key20210729111942_b77-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5152\/eurjrheum.2020.20007","article-title":"Tofacitinib-induced remission simultaneously in arthritis and vitiligo","volume":"8","author":"Scheinberg","year":"2021","journal-title":"Eur J Rheumatol"},{"key":"key20210729111942_b78-ETM-0-0-10229","first-page":"9","article-title":"Minocycline protects melanocytes against H2O2-induced cell death via JNK and p38 MAPK pathways","volume":"22","author":"Song","year":"2008","journal-title":"Int J Mol Med"},{"key":"key20210729111942_b79-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1529-8019.2010.01328.x","article-title":"Oral minocycline in the treatment of vitiligo-a preliminary study","volume":"23","author":"Parsad","year":"2010","journal-title":"Dermatol Ther"},{"key":"key20210729111942_b80-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/0378-6323.125479","article-title":"Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris","volume":"80","author":"Singh","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"key20210729111942_b81-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/archderm.135.4.407","article-title":"Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris","volume":"135","author":"Njoo","year":"1999","journal-title":"Arch Dermatol"},{"issue":"240856","key":"key20210729111942_b82-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/240856","article-title":"Narrow-band ultraviolet B versus oral minocycline in treatment of unstable vitiligo: A prospective comparative trial","volume":"2014","author":"Siadat","year":"2014","journal-title":"Dermatol Res Pract"},{"key":"key20210729111942_b83-ETM-0-0-10229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/TJD.TJD_38_19","article-title":"Statins role in vitiligo: A mini-review","volume":"14","author":"Al-Kuraishy","year":"2020","journal-title":"Turkish J Dermatol"},{"key":"key20210729111942_b84-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J Invest Dermatol"},{"key":"key20210729111942_b85-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jamadermatol.2017.6401","article-title":"Atorvastatin in combination with narrowband UV-B in adult patients with active vitiligo: A randomized clinical trial","volume":"154","author":"Nguyen","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"34","key":"key20210729111942_b86-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.4103\/2277-9175.203159","article-title":"A comparison of betamethasone valerate 0.1% cream twice daily plus oral simvastatin versus betamethasone valerate 0.1% Cream alone in the treatment of vitiligo patients","volume":"6","author":"Iraji","year":"2017","journal-title":"Adv Biomed Res"},{"issue":"7","key":"key20210729111942_b87-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-3-7","article-title":"Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo","volume":"3","author":"No\u00ebl","year":"2004","journal-title":"Lipids Health Dis"},{"key":"key20210729111942_b88-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jaad.2016.06.015","article-title":"A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo","volume":"76","author":"Vanderweil","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b89-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jsps.2012.12.003","article-title":"Methotrexate for the treatment of generalized vitiligo","volume":"21","author":"Alghamdi","year":"2013","journal-title":"Saudi Pharm J"},{"key":"key20210729111942_b90-ETM-0-0-10229","first-page":"705","article-title":"Low-dose methotrexate for vitiligo","volume":"16","author":"Garza-Mayers","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"key20210729111942_b91-ETM-0-0-10229","first-page":"16","article-title":"Efficacy of methotrexate in vitiligo","volume":"17","author":"Nageswaramma","year":"2018","journal-title":"IOSR J Dental Med Sci"},{"key":"key20210729111942_b92-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000433424","article-title":"A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo","volume":"231","author":"Singh","year":"2015","journal-title":"Dermatology"},{"issue":"e13586","key":"key20210729111942_b93-ETM-0-0-10229","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13586","article-title":"Combination of oral methotrexate and oral mini-pulse dexamethasone vs. either agent alone in vitiligo treatment with follow up by dermoscope","volume":"33","author":"ElGhareeb","year":"2020","journal-title":"Dermatol Ther"},{"key":"key20210729111942_b94-ETM-0-0-10229","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/CDR.CDR_13_18","article-title":"Comparative study of safety and efficacy of oral betamethasone pulse therapy and azathioprine in vitiligo","volume":"3","author":"Madarkar","year":"2019","journal-title":"Clin Dermatol Rev"},{"key":"key20210729111942_b95-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/09546630600791442","article-title":"The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients","volume":"17","author":"Radmanesh","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"key20210729111942_b96-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"528","DOI":"10.4103\/ijdvl.IJDVL_656_18","article-title":"Cyclosporine in treatment of progressive vitiligo: An open-label, single-arm interventional study","volume":"85","author":"Taneja","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"key20210729111942_b97-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1097\/DSS.0000000000001190","article-title":"Efficacy of cyclosporine after autologous noncultured melanocyte transplantation in localized stable vitiligo-a pilot, open label, comparative study","volume":"43","author":"Mutalik","year":"2017","journal-title":"Dermatol Surg"},{"key":"key20210729111942_b98-ETM-0-0-10229","author":"Bishnoi"},{"key":"key20210729111942_b99-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1210\/en.2017-03230","article-title":"How UV light touches the brain and endocrine system through skin, and Why","volume":"159","author":"Slominski","year":"2018","journal-title":"Endocrinology"},{"key":"key20210729111942_b100-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/php.12642","article-title":"Skin exposure to ultraviolet B rapidly activates systemic neuroendocrine and immunosuppressive responses","volume":"93","author":"Skobowiat","year":"2017","journal-title":"Photochem Photobiol"},{"key":"key20210729111942_b101-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/jid.2014.450","article-title":"UVB activates hypothalamic-pituitary-adrenal axis in C57BL\/6 Mice","volume":"135","author":"Skobowiat","year":"2015","journal-title":"J Invest Dermatol"},{"key":"key20210729111942_b102-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.0906-6705.2004.00221.x","article-title":"Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes","volume":"13","author":"Wu","year":"2004","journal-title":"Exp Dermatol"},{"key":"key20210729111942_b103-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaad.2016.12.041","article-title":"The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo","volume":"76","author":"Mohammad","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b104-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for Vitiligo: A systematic review and Meta-analysis","volume":"153","author":"Bae","year":"2017","journal-title":"JAMA Dermatol"},{"key":"key20210729111942_b105-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/phpp.12277","article-title":"Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: A Meta-analysis","volume":"33","author":"Li","year":"2017","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"key20210729111942_b106-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bjd.17150","article-title":"Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo","volume":"180","author":"Tovar-Garza","year":"2019","journal-title":"Br J Dermatol"},{"key":"key20210729111942_b107-ETM-0-0-10229","author":"Phan"},{"key":"key20210729111942_b108-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jid.2019.11.031","article-title":"Apremilast in Combination with narrowband UVB in the treatment of vitiligo: A 52-week monocentric prospective randomized placebo-controlled study","volume":"140","author":"Khemis","year":"2020","journal-title":"J Invest Dermatol"},{"key":"key20210729111942_b109-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: A randomized multicenter trial","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol"},{"key":"key20210729111942_b110-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"NP46","DOI":"10.1093\/asj\/sjz250","article-title":"Efficacy of combination therapy with fractional carbon dioxide laser and Ultraviolet B phototherapy for vitiligo: A systematic review and Meta-analysis","volume":"40","author":"Chang","year":"2020","journal-title":"Aesthet Surg J"},{"key":"key20210729111942_b111-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1365-2133.2006.07584.x","article-title":"Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo","volume":"156","author":"Wu","year":"2007","journal-title":"Br J Dermatol"},{"key":"key20210729111942_b112-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1468-3083.2006.01413.x","article-title":"Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo","volume":"20","author":"Parsad","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20210729111942_b113-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1468-3083.2007.02283.x","article-title":"Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: An open prospective comparative study","volume":"21","author":"Bhatnagar","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20210729111942_b114-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/s0738-081x(97)00133-8","article-title":"Psoralen photochemotherapy for vitiligo","volume":"15","author":"Grimes","year":"1997","journal-title":"Clin Dermatol"},{"key":"key20210729111942_b115-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14728214.2020.1712358","article-title":"Emerging drugs for the treatment of vitiligo","volume":"25","author":"Karagaiah","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"key20210729111942_b116-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/phpp.12015","article-title":"Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo-a randomized bilateral comparison study","volume":"29","author":"Shi","year":"2013","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"key20210729111942_b117-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1600-0781.2011.00587.x","article-title":"The effect of 308nm excimer laser on segmental vitiligo: A retrospective study of 80 patients with segmental vitiligo","volume":"27","author":"Do","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"key20210729111942_b118-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-015-0164-2","article-title":"Efficacy and safety of 308-nm monochromatic excimer lamp versus other phototherapy devices for vitiligo: A systematic review with meta-analysis","volume":"17","author":"Lopes","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"key20210729111942_b119-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jaad.2015.11.044","article-title":"The efficacy of 308-nm excimer laser\/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs)","volume":"74","author":"Bae","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key20210729111942_b120-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3889\/oamjms.2018.059","article-title":"An innovative therapeutic protocol for vitiligo: Experience with the use of fraxel herbium laser, topical latanoprost and successive irradiation with UVA-1 laser","volume":"6","author":"Lotti","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"key20210729111942_b121-ETM-0-0-10229","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.det.2016.11.010","article-title":"Depigmentation therapies for vitiligo","volume":"35","author":"Grimes","year":"2017","journal-title":"Dermatol Clin"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T08:19:56Z","timestamp":1627546796000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.10229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":121,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,5,25]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.10229","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"article-number":"797"}}